Nivolumab As Second-Line Treatment of Patients with Metastatic Renal Cell Carcinoma with High or Normal Fibrinogen Levels: A Prospective, Cohort Study
JOURNAL OF CLINICAL ONCOLOGY（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined